TGFB1 and colorectal carcinoma: We have previously assessed the relevance of consensus-molecular subgroups (CMS), grouping CRC according to their gene-signature in four different subtypes, and found that OS in CMS4 (defined by EMT and an activated tissue growth factor (TGF)-β pathway making this subgroup more chemo-resistant) favored FOLFIRI plus cetuximab over FOLFIRI plus bevacizumab.